Last reviewed · How we verify

NCT03445312: Salient

Safety and Effectiveness of a Laboratory Intervention to Effectively NOT Treat Asymptomatic Bacteriuria

Completed Last updated 1 June 2020
What this trial tests

trial testing not processing urine cultures in Asymptomatic Bacteriuria in 1,394 participants. Completed in 15 November 2019.

Timeline
31 August 2017
Primary endpoint
15 May 2019
15 November 2019

Quick facts

Lead sponsorMount Sinai Hospital, Canada
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,394
Start date31 August 2017
Primary completion15 May 2019
Estimated completion15 November 2019
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Mount Sinai Hospital, Canada

Who can join

Eligibility, any sex, with Asymptomatic Bacteriuria or Urinary Tract Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational cohort study of 1000 consecutive patients on medical and surgical wards at the Mount Sinai Hospital in Toronto who have a mid-stream urine culture ordered. When these cultures are ordered or received in the laboratory, a message is posted that the specimen will not be processed in the laboratory unless a call is received to say that the patient has local urinary symptoms. The goal is to establish whether not processing mid-stream urine cultures is safe.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Asymptomatic Bacteriuria

Currently open trials in the same condition.

Other Mount Sinai Hospital, Canada trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03445312.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing